In-silico study reveals potential antitubercular drug targets unique to Mycobacterium tuberculosis H37Rv

Maurya S., Alhazmi A., Vidyarthi A. S., Jain A., Singh V., Khan F., ...More

MINERVA BIOTECHNOLOGY AND BIOMOLECULAR RESEARCH, vol.34, no.2, pp.71-79, 2022 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 34 Issue: 2
  • Publication Date: 2022
  • Doi Number: 10.23736/s2724-542x.21.02849-2
  • Journal Name: MINERVA BIOTECHNOLOGY AND BIOMOLECULAR RESEARCH
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED)
  • Page Numbers: pp.71-79
  • Keywords: Mycobacterium tuberculosis, Proteome, Genes, essential, Gene ontology, IDENTIFICATION
  • Bursa Uludag University Affiliated: No

Abstract

BACKGROUND: Developing safe drugs for tuberculosis (TB), is a major challenge due to upsurge in drug resistance, hepatotoxicity, and the presence of Mycobacterium tuberculosis (Mtb) targets orthologs in human and its non-pathogenic host E. coli. Prostaglandin G/H synthase-2 and 30S ribosomal-S12 protein of Mtb show 100 and 48% similarity with human proteins respectively. Thus, targeting these Mtb proteins by p-aminosalicylic acid and streptomycin for the treatment of TB adversely affect human metabolism, and warrants to identify novel and unique drug targets of Mtb.